B6.129P2-Irf8tm1Hor/Kctt

Status

Available to order

EMMA IDEM:02414
International strain nameB6.129P2-Irf8tm1Hor/Kctt
Alternative nameIrf8-/-
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolIrf8tm1Hor,
Gene/Transgene symbolIrf8

Information from provider

ProviderIvan Horak
Provider affiliationLeibniz-Institut für Molekulare Pharmakologie
Genetic informationA PGK-neomycin gene was inserted into the second exon of the Irf8 gene, disrupting sequences encoding the DNA binding domain.
Phenotypic informationAbnormal hematopoiesis.
References
  • Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis.;Fehr T, Schoedon G, Odermatt B, Holtschke T, Schneemann M, Bachmann M F, Mak T W, Horak I, Zinkernagel R M, ;1997;The Journal of experimental medicine;185;921-31; 9120398
  • Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction.;Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K, ;1997;The Journal of experimental medicine;186;1523-34; 9348310
  • Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression.;Giese N A, Gabriele L, Doherty T M, Klinman D M, Tadesse-Heath L, Contursi C, Epstein S L, Morse H C, ;1997;The Journal of experimental medicine;186;1535-46; 9348311
  • Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.;Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring J F, Rosenbauer F, Huhn D, Wittig B, Horak I, Neubauer A, ;1998;Blood;91;22-9; 9414265
  • Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein.;Scheller M, Foerster J, Heyworth C M, Waring J F, Löhler J, Gilmore G L, Shadduck R K, Dexter T M, Horak I, ;1999;Blood;94;3764-71; 10572090
  • ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells.;Schiavoni Giovanna, Mattei Fabrizio, Sestili Paola, Borghi Paola, Venditti Massimo, Morse Herbert C, Belardelli Filippo, Gabriele Lucia, ;2002;The Journal of experimental medicine;196;1415-25; 12461077
  • AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency.;Schwieger Maike, Löhler Jürgen, Friel Jutta, Scheller Marina, Horak Ivan, Stocking Carol, ;2002;The Journal of experimental medicine;196;1227-40; 12417632
  • Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells.;Aliberti Julio, Schulz Oliver, Pennington Daniel J, Tsujimura Hideki, Reis e Sousa Caetano, Ozato Keiko, Sher Alan, ;2003;Blood;101;305-10; 12393690
  • Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.;Holtschke T, Löhler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch K P, Gabriele L, Waring J F, Bachmann M F, Zinkernagel R M, Morse H C, Ozato K, Horak I, ;1996;Cell;87;307-17; 8861914

Information from EMMA

Archiving centreKarolinska Institutet, Stockholm, Sweden

Disease and phenotype information

MGI allele-associated human disease models

Orphanet associated rare diseases, based on orthologous gene matching

    • Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency / Orphanet_319600
MGI phenotypes (allele matching)
  • premature death / MGI
  • abnormal definitive hematopoiesis / MGI
  • increased chronic myelocytic leukemia incidence / MGI
  • increased B-1b cell number / MGI
  • decreased follicular B cell number / MGI
  • increased marginal zone B cell number / MGI
  • increased leukocyte cell number / MGI
  • abnormal erythropoiesis / MGI
  • increased bone marrow cell number / MGI
  • increased granulocyte number / MGI
  • enlarged liver / MGI
  • enlarged spleen / MGI
  • spleen hyperplasia / MGI
  • enlarged lymph nodes / MGI
  • abnormal megakaryocyte morphology / MGI
  • increased susceptibility to viral infection / MGI
  • increased immunoglobulin level / MGI
  • increased lymphocyte cell number / MGI
  • increased B cell number / MGI
  • decreased lymphocyte cell number / MGI
  • decreased B cell number / MGI
  • decreased T cell number / MGI
  • abnormal cytotoxic T cell physiology / MGI
  • increased macrophage cell number / MGI
  • abnormal plasma cell number / MGI
  • increased mature B cell number / MGI
  • increased spleen red pulp amount / MGI
  • decreased interferon-gamma secretion / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • increased lymphoma incidence / MGI
  • abnormal humoral immune response / MGI

Literature references

  • Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis.;Fehr T, Schoedon G, Odermatt B, Holtschke T, Schneemann M, Bachmann M F, Mak T W, Horak I, Zinkernagel R M, ;1997;The Journal of experimental medicine;185;921-31; 9120398
  • Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction.;Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K, ;1997;The Journal of experimental medicine;186;1523-34; 9348310
  • Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression.;Giese N A, Gabriele L, Doherty T M, Klinman D M, Tadesse-Heath L, Contursi C, Epstein S L, Morse H C, ;1997;The Journal of experimental medicine;186;1535-46; 9348311
  • Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.;Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring J F, Rosenbauer F, Huhn D, Wittig B, Horak I, Neubauer A, ;1998;Blood;91;22-9; 9414265
  • Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein.;Scheller M, Foerster J, Heyworth C M, Waring J F, Löhler J, Gilmore G L, Shadduck R K, Dexter T M, Horak I, ;1999;Blood;94;3764-71; 10572090
  • ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells.;Schiavoni Giovanna, Mattei Fabrizio, Sestili Paola, Borghi Paola, Venditti Massimo, Morse Herbert C, Belardelli Filippo, Gabriele Lucia, ;2002;The Journal of experimental medicine;196;1415-25; 12461077
  • AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency.;Schwieger Maike, Löhler Jürgen, Friel Jutta, Scheller Marina, Horak Ivan, Stocking Carol, ;2002;The Journal of experimental medicine;196;1227-40; 12417632
  • Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells.;Aliberti Julio, Schulz Oliver, Pennington Daniel J, Tsujimura Hideki, Reis e Sousa Caetano, Ozato Keiko, Sher Alan, ;2003;Blood;101;305-10; 12393690
  • Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.;Holtschke T, Löhler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch K P, Gabriele L, Waring J F, Bachmann M F, Zinkernagel R M, Morse H C, Ozato K, Horak I, ;1996;Cell;87;307-17; 8861914

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).